September 1, 2024
PRESS RELEASE

MultiplexDX invests in StratifAI to revolutionize breast cancer care

We are excited to announce our investment in StratifAI, an innovative startup dedicated to revolutionizing cancer diagnostics and treatment. StratifAI is developing multimodal AI models that analyze routine histological images (H&E slides) and clinical data to provide vital prognostic insights. Their work aligns perfectly with MultiplexDX's mission to enhance precision oncology and improve patient outcomes.

One of StratifAI’s remarkable achievements is an advanced AI-based prognostic test for breast cancer. This test evaluates the need for adjuvant chemotherapy directly from H&E images, helping to reduce unnecessary treatments and provide faster, more accessible results compared to traditional genomic tests.

This collaboration represents a significant step forward in personalized medicine. By combining our expertise with StratifAI’s groundbreaking innovations, we are opening doors to a new era in diagnostics—one where artificial intelligence empowers us to deliver the most effective treatments for breast cancer patients. We’re proud to be part of this journey.

For more information about StratifAI, visit stratifai.com.

About MultiplexDX

MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).

MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.

Find out more about MultiplexDX on Corporate website, Facebook, LinkedIn, Twitter

Other latest

MultiplexDX News